deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06930755

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer

Sponsor: Nerviano Medical Sciences

Conditions Ovarian Cancer
Interventions NMS-03305293 Topotecan
Updated 6 times since 2025 Last updated: Jan 20, 2026 Started: Jan 31, 2026 Primary completion: May 31, 2027 Completion: Sep 26, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06930755, this PHASE1 trial focuses on Ovarian Cancer and remains actively recruiting participants. Sponsored by Nerviano Medical Sciences, it has been updated 6 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2025 – ~Aug 2025 · 3 months · monthly snapshotNot Yet Recruiting~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshotRecruiting~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshotRecruiting~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

6 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1

  2. Dec 2025 — Feb 2026 [monthly]

    Recruiting PHASE1

  3. Nov 2025 — Dec 2025 [monthly]

    Recruiting PHASE1

  4. Sep 2025 — Nov 2025 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  5. Aug 2025 — Sep 2025 [monthly]

    Not Yet Recruiting PHASE1

▶ Show 1 earlier version

  1. May 2025 — Aug 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Nerviano Medical Sciences
Data source: Nerviano Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations